Neomycin And Polymyxin B Sulfates And Dexamethasone

   
Google
 
Web NewDrugInformation.com

Neomycin And Polymyxin B Sulfates And Dexamethasone


Drug - Neomycin And Polymyxin B Sulfates And Dexamethasone
The trade name of the product as shown on the labeling.

Dosage - SUSPENSION/DROPS; OPHTHALMIC
The product dosage form and route separated by a semi-colon.

Active Ingredient(s) - Dexamethasone; Neomycin Sulfate; Polymyxin B Sulfate
Multiple ingredients are in alphabetical order.

Strength - 0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML
The potency of the active ingredient(s), Dexamethasone; Neomycin Sulfate; Polymyxin B Sulfate. May repeat for multiple part products.

Applicant - ALCON UNIVERSAL
The firm name holding legal responsibility for Neomycin And Polymyxin B Sulfates And Dexamethasone. The firm name is condensed to a maximum twenty character unique string.

New Drug Application (NDA) Number - 062721
The FDA assigned number to Neomycin And Polymyxin B Sulfates And Dexamethasone. Format is nnnnnn.

Product Number - 001
The FDA assigned number to identify Neomycin And Polymyxin B Sulfates And Dexamethasone. Each strength is a separate product. May repeat for multiple part products. Format is nnn.

Therapeutic Equivalence (TE) Code - AT
The TE Code indicates the therapeutic equivalence rating of generic to innovator Rx products.

Approval Date - Nov 17, 1986
The date Neomycin And Polymyxin B Sulfates And Dexamethasone was approved as stated in the FDA approval letter to the applicant. The format is Mmm dd, yyyy. Products approved prior to the January 1, 1982 contain the phrase: "Approved prior to Jan 1, 1982".

Reference Listed Drug (RLD) - No
The pioneer or innovator of Neomycin And Polymyxin B Sulfates And Dexamethasone. The RLD identifies the product Abbreviated New Drug Applications (ANDA) use as a reference. Format is Yes or No.

Type - RX
The group or category of approved drugs Neomycin And Polymyxin B Sulfates And Dexamethasone is in. Format is RX, OTC, DISCN.

Applicant Full Name - Alcon Universal Ltd
The full name of the firm holding legal responsibility for the new application of Neomycin And Polymyxin B Sulfates And Dexamethasone.

Neomycin And Polymyxin B Sulfates And Dexamethasone


Neomycin And Polymyxin B Sulfates And Dexamethasone 0.1%;eq 3.5mg Base/gm;10,000 Units/gm Ointment; Ophthalmic
Dexacidin 0.1%;eq 3.5mg Base/ml;10,000 Units/ml Suspension/drops; Ophthalmic
Dexasporin 0.1%;eq 3.5mg Base/ml;10,000 Units/ml Suspension/drops; Ophthalmic
Dexasporin 0.1%;eq 3.5mg Base/ml;10,000 Units/ml Suspension/drops; Ophthalmic
Maxitrol 0.1%;eq 3.5mg Base/ml;10,000 Units/ml Suspension/drops; Ophthalmic
Maxitrol 0.1%;eq 3.5mg Base/ml;10,000 Units/ml Suspension/drops; Ophthalmic
Neomycin And Polymyxin B Sulfates And Dexamethasone 0.1%;eq 3.5mg Base/ml;10,000 Units/ml Suspension/drops; Ophthalmic
Dexasporin 0.1%;eq 3.5mg Base/gm;10,000 Units/gm Ointment; Ophthalmic
Maxitrol 0.1%;eq 3.5mg Base/gm;10,000 Units/gm Ointment; Ophthalmic
Neomycin And Polymyxin B Sulfates And Dexamethasone 0.1%;eq 3.5mg Base/gm;10,000 Units/gm Ointment; Ophthalmic

NewDrugInformation